Benralizumab

NRA’s $35 Million Loss: Membership Dues Plummet Amidst Criticism

The NRA’s 2023 revenue plummeted to $178 million, a dramatic decrease from its peak fundraising years in the mid-2010s when it exceeded $400 million annually. This represents a historic low, with overall income less than member dues alone in four of the past ten years. The decline is largely attributed to a five-year drop in member dues, reaching levels unseen since at least the early 2000s. The 2023 member dues of $61.8 million are a stark contrast to the nearly $223 million collected a decade prior. Financial documents indicate further revenue decreases are projected for 2024.

Read More

New Asthma Treatment: Hype vs. Reality—Expensive Injections, Limited Access

Research from King’s College London reveals benralizumab, an injectable drug already used for severe cases, as the first new asthma attack treatment in 50 years. Targeting eosinophils, a type of white blood cell contributing to lung inflammation, the therapy significantly reduced treatment failure rates compared to steroids (45% vs. 74%) in a 158-person trial. This new approach offers improved symptoms, quality of life, and reduced hospitalizations, potentially impacting the two million asthma attacks annually in the UK. While further large-scale trials are needed, the findings suggest a potential “game-changer” in asthma and COPD treatment.

Read More